https://www.spandidos-publications.com/10.3892/ol.2025.15178
Alectinib efficacy in advanced lung adenocarcinoma with coexistence of a novel ALK-MTUS2 and...
Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.
https://www.mskcc.org/cancer-care/clinical-trials/25-097
A Phase 3 Study Comparing Neladalkib (NVL-655) With Alectinib in People With Advanced Non-Small...
Full Title A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With...
https://www.cancerresearchuk.org/about-cancer/treatment/drugs/alectinib
Alectinib (Alecensa) | Cancer Research UK
Alectinib is a type of targeted cancer drug. It is a treatment for lung cancer. Find out about how you have it, possible side effects and other important...
cancer researchalectinibalecensauk
https://www.cincinnatichildrens.org/service/c/clinical-trials/studies/GO42286
GO42286: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric...
GO42286: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors
https://www.cancer.gov/about-cancer/treatment/drugs/alectinib
Alectinib - NCI
This page contains brief information about alectinib and a collection of links to more information about the use of this drug, research results, and ongoing...
alectinibnci
https://www.news-medical.net/news/20151211/Alecensa-(alectinib)-approved-for-treatment-of-people-with-advanced-ALK-positive-NSCLC.aspx
Alecensa (alectinib) approved for treatment of people with advanced ALK-positive NSCLC
Jun 19, 2019 - The U.S. Food and Drug Administration today approved Alecensa (alectinib) to treat people with advanced (metastatic) ALK-positive non-small cell lung cancer...